vzphotos Shares of AbbVie Inc. (NYSE:ABBV) closed nearly 5% lower after the first quarter earnings announcement last week, despite the company beating revenue and EPS expectations. Apparently, investors are worried about the erosion of Humira and the most recent move by Cigna which will offer a biosimilar version of Humira with no out-of-pocket cost to…
vzphotos Overview AbbVie is a research-based biopharmaceutical company with immunology, oncology, aesthetics, and neuroscience expertise. In immunology, AbbVie is known for one of the most sold drugs of all time, Humira, which has generated gross revenue of $21 billion at the peak year. Pharmaceutical companies are challenging to value because, as in the case of…
PM Images Shareholders of AbbVie Inc. (NYSE:ABBV) should be thrilled with its overall results, as just the appreciation over the past decade has outperformed the market. Shares of ABBV have appreciated by 248.90% over the past decade and by 104.87% over the past 5 years. The SPDR S&P 500 ETF Trust (SPY), which is what…
vzphotos There’s no sugarcoating the fact that AbbVie (NYSE:ABBV), the biggest healthcare stock by market capitalisation after Eli Lilly and Company (LLY), has seen dismal full-year results for 2023 last month with a 6.4% decline in revenue and a huge 59% drop in reported earnings per share [EPS]. Still, its price is on the up…
JHVEPhoto I’ve underestimated biopharma company AbbVie Inc.’s (NYSE:ABBV) ability to overcome the near- and medium-term headwinds from Humira’s LOE. I assessed that the risk/reward of ABBV was well-balanced in my previous update in late November 2023. However, that Hold/Neutral thesis has proved to be too cautious. I had anticipated selling pressure to intensify, potentially leading…
Gajus We previously covered AbbVie Inc. (NYSE:ABBV) in October 2023, discussing its mixed prospects as Humira’s revenue erosion may further worsen with the US FDA approval of two directly interchangeable biosimilars. Combined with the stock’s sideways movement over the past few quarters, we believe that the stock offers a mixed growth/ dividend investment story until…
Aslan Alphan/iStock via Getty Images Do you wonder why companies are willing to pay what appears to be a hefty premium for other companies? If so, take a look at the four points below. What happened? In the biggest blockbuster acquisition since acquiring Allergen for over $60 billion in 2019, AbbVie (NYSE:ABBV) has agreed to…
RomoloTavani AbbVie Inc. (NYSE:ABBV) investors must wonder what it must take for market participants to move past the company’s Humira headwinds to focus on its ex-Humira growth products instead. Therefore, I’m pleasantly surprised with the announcement earlier today that AbbVie will acquire Immunogen (IMGN) for about $10B in cash. AbbVie will pay a price of…
Kemal Yildirim AbbVie (NYSE:ABBV) is one of the largest companies in the global pharmaceutical market. The company is headquartered in North Chicago. Thesis Since writing our last article, the company’s share price has continued a downward movement, in line with our expectations. However, AbbVie’s published financial results for the third quarter of 2023 were a…
JHVEPhoto AbbVie Inc. (NYSE:ABBV) investors breathed a sigh of relief as ABBV has recovered remarkably from its June 2023 lows despite posting a prelim-Q2 earnings release in early July that likely spooked some investors. However, ABBV dip buyers held those lows robustly, demonstrating to unconvinced investors that the market had already priced in significant pessimism….
Hailshadow The Decline of Humira For the first seven years of AbbVie’s (NYSE:ABBV) existence as a public company, its top selling drug Humira made up over 60% of the company’s total sales on average. By some accounts, based on cumulative sales since its launch in 2003, Humira has been the top selling drug of all…